Flint Capital is an international venture capital fund investing across the US, Europe, and Israel with offices in Boston, and Tel Aviv. It invests in promising entrepreneurs and technology ventures with global ambitions. Its unique global positioning enables them to support Israeli and European ventures on both sides of the ocean, as they expand into the US market. This Bridge strategy and its broad network of entrepreneurs, industry experts, and investment funds provide them with access to high-quality investment opportunities.

Flint Capital

Founded by Shelly Hod Moyal and Mor Assia, iAngels is a women-led venture capital firm and one of Israel's most active and recognized investors. Combining a deep, proprietary due-diligence process alongside best-in-class reporting, iAngels provides a window into Israel's extremely rich startup world and has a proven ability to generate and deliver superior VC returns. iAngels believes in going beyond and backs those who do, partnering with some of the highest-caliber entrepreneurs in the nation.

iAngels

Welltech Ventures is the first and leading venture capital firm in Israel solely focused on the wellness space. Our high-level experience, thought leadership, vast global network, and founder-focused, fast-paced culture makes us the partner of choice for Israel’s most promising and profitable well-tech entrepreneurs. We’re focused on investing in early-stage startups that are harnessing new technologies to improve people’s lives in ways we never dreamed possible, innovating in areas such as remote care, preventive medicine, mental health, fitness, nutrition, sustainability, and longevity.

Welltech Ventures

Group 11 invests in visionary entrepreneurs who are utilizing the unstoppable momentum of AI and FinTech to redraw the landscape of their respective industries. With a goal of creating change across generations and building long term value through technology, Group 11 has emerged as a coveted partner to veteran entrepreneurs at the forefront of their fields.  Since its inception in 2012, the top-decile performing firm has deployed over $580 million across six funds in some of the world’s most prominent and disruptive technology companies, including: Tipalti, Navan, Next Insurance, HomeLight, Sunbit, Masterschool, Healthee, Dream, and BridgeWise.

Group 11

Antidote Health

Antidote Health offers an AI-based health platform that helps people receive proper medical treatment. Antidote Health's technology streamlines patient screening and augments the doctor's decision-making process, removing the burden of administrative tasks from the doctor and improving the quality of the doctor-patient experience. In addition to offering all the benefits of a standard telehealth platform, Antidote Health's platform is designed to address the added layer of social health, creating a health ripple effect, spreading from doctors to patients, to families and communities which loops back to positively impact the lives of everyone involved: patients, doctors, and the communities they live in.

<div><p>Antidote Health is a B2C company that provides 24/7 virtual acute and primary care services, connecting patients to clinicians via a chatbot and video calls. As of January 2021, the platform was available in New York, New Jersey, Florida, Michigan, and North Carolina, with plans to expand into more US states in 2022.</p></div>

More important now than ever, telehealth will long outlast the pandemic that drove its growth.

Telehealth

<div>
  <p>
    Antidote Health is a B2C company that provides 24/7 virtual acute and primary care services, connecting patients to clinicians via a chatbot and video calls. As of January 2021, the platform was available in New York, New Jersey, Florida, Michigan, and North Carolina, with plans to expand into more US states in 2022.
  </p>
  <p>
    In March 2022 the company raised USD 22 million in a Series A funding round co-led by third-time investor Flint Capital, iAngels, and Group 11. The funds have been earmarked to bolster its market presence, expand its range of services across the US, and develop new products through R&amp;D. The company is specifically looking into developing new services, which would integrate AI screening and clinical decision support system capabilities.
  </p>
</div>


<div>
  <p>
    Nice Healthcare is a US based telehealth company with a focus on primary care services to business-to-business (B2B) clients. Once the employer signs its employees with Nice (at a cost of USD 30 to USD 36 per employee per month), employees do not have to incur out of pocket expenses for Nice services and can schedule virtual or home visits within the time frames specified by the company. It connects patients with practitioners through a mobile app over video calls or text messages. Members can also request home visits which will be completed within a few hours, as claimed by the company. As of March 2022, Nice was operating in twelve states, and had over 400 small and medium enterprises (SMEs).
  </p>
  <p>
    In March 2022, the company raised USD 30 million in Series A financing led by DNA Capital which has been earmarked to expand its platform&rsquo;s reach among small and medium businesses. Additionally, the company is hiring three members for its management team to support the continuing growth of the organization.
  </p>
  <p>
  </p>
</div>


Nice Healthcare

<div>
  <p>
    Amicomed is a cloud-based Software-as-a-Service (SaaS) platform which provides blood pressure monitoring services. It collects blood pressure data of patients from at-home devices, applies algorithms, and assesses the fluctuations in the blood pressure. Physicians can be connected and provided with blood pressure data of their patients in order to facilitate their workload, enabling more personalized management of patients regarding medication and lifestyle indications. 
  </p>
  <p>
    Amicomed can also recommend actionable and personalized lifestyle interventions such as daily diet and exercises via virtual coaching.
  </p>
</div>


Amicomed

<div>
  <p>
    Winston is a men&rsquo;s health telemedicine platform that treats common issues impacting men such as sexual problems, hair loss, acne, and cold sores. Winston allows patients to consult doctors, place orders for prescription drugs, and offers free delivery to the homes of patients. 
  </p>
  <p>
    The Toronto-based company aims to avoid men deferring doctor visits or withholding sensitive information. The consultation fee is covered by the provincial health plan, but the prescriptions are billed to the customer.
  </p>
</div>


Winston

<div>
  <p>
    Eko Health is a cardiopulmonary digital health company that aims to improve heart and lung care for patients using sensors and artificial intelligence. The company produces connected handheld digital stethoscopes with electrocardiogram functionality to detect heart rhythm abnormalities using artificial intelligence (AI) algorithms. In 2020, the company obtained 501(k) FDA clearance for multiple algorithms that help detect heart murmurs and atrial fibrillation, or AFib. These algorithms were used in 2022 to develop the Eko App, which pairs to the company's stethoscopes for report generation, information sharing and carrying out examinations. 
  </p>
  <p>
    The company operates on a fee per unit B2B2C model and a D2C model, where it provides its technology to medical practitioners or patients for diagnostic purposes.
  </p>
  <p>
    In February 2023, Eko 
    <a href="https://sp-edge.com/updates/16677">
      launched SENSORA
    </a>
    , a cardiac disease detection platform that combines the company&rsquo;s existing digital stethoscopes with a machine learning-based platform. The platform enables primary care physicians to detect structural murmurs and assess heart arrhythmias by using a database of heart sounds to compare and identify anomalies in a patient's heart beat. 
  </p>
  <p>
    In April 2024, Eko 
    <a href="https://sp-edge.com/updates/28111">
      obtained FDA 510(k) clearance
    </a>
     for its AI-aided cardiac tool, Eko Low Ejection Fraction Tool (ELEFT). The tool is designed to assist providers in early detection of low ejection fraction, a significant sign of heart failure.
  </p>
  <p>
    <b>Funding and financials</b>
  </p>
  <p>
    In March 2022, raised a further USD 30 million in an extension to its Series C round, which began November 2020. The total funds raised by the company stood at USD 126 million as of March. These funds have been allocated to support further commercialization efforts and develop new products for the company.
  </p>
  <p>
  </p>
  <p>
  </p>
  <p>
  </p>
</div>


<div>
  <p>
    Dialogue partners with employers and health insurers to offer telehealth services to their employees and members. The users have 24/7 access to doctors, nurses, and other healthcare professionals via audio, video, and chat options for wide arrays of physical and mental health needs, artificial intelligence-enabled (AI-enabled) triage, referrals, and prescription renewals. 
  </p>
  <p>
    The company launched its trademarked Integrated Health Platform in January 2021 to consolidate its virtual care,  wellness programs, mental healthcare services, and Employee Assistance Program (EAP) onto a single platform. The company claims to be the only integrated health and wellness B2B platform in Canada. 
  </p>
  <p>
    <b>Key Customers and partnerships</b>
  </p>
  <p>
    Dialogue had direct relationships with over 2,000 customers across Canada and Germany as of December 2020 and served around 50,000 organizations through these partnerships. In addition, the number of members with access to the virtual platform topped 1 million in January 2021. 
  </p>
  <p>
    <b>Fundings and financials</b>
  </p>
  <p>
    As of March 2021, Dialogue was planning to raise CAD 100 million (USD 80 million) from an initial public offering that will be listed on the Toronto Stock Exchange under the ticker symbol &ldquo;CARE.&rdquo; 
  </p>
  <p>
    In Q2 2023, net losses reduced significantly YoY to CAD 5.8 million (USD 4.3 million) from CAD 8.4 million (USD 6.3 million) in Q2 2022. Top-line revenue met internal expectations, growing 17.2% YoY to CAD 25.5 million (USD 19.0 million), driven by &nbsp;an increase in new members (by 18.6% YoY), 
    an expansion of the attach rate as existing customers added more services, and full-quarter contributions from Tictrac.
     
    Dialogue Health has not provided any forward-looking guidance as the company has entered into an agreement to be 
    <a href="https://investors.dialogue.co/English/news/news-details/2023/Dialogue-to-be-Acquired-by-Sun-Life/default.aspx">
      <u>acquired by financial services company Sun Life Financial</u>
    </a>
     for a consideration of CAD 365 million (USD 270 million) or CAD 5.15 (USD 3.82) per share. The transaction is expected to close in Q4 2023. Post acquisition, Dialogue will delist from the Toronto Stock Exchange but will continue to operate as a standalone entity under the &ldquo;Sun Life Canada&rdquo; brand from its head office in Qu&eacute;bec. 
  </p>
  <p>
  </p>
</div>


Dialogue

IoT is used by most telehealth providers to operate virtual services

All telehealth players are involved in digital health via virtual offerings

Industry players offer varying degrees of personalization for each target audience

Some players offer technology and platforms to healthcare providers, converting physical-only services into virtual services

Specific telehealth offerings focus on diversity and inclusion, providing care to LGBTQ+ or BIPOC populations

Generative AI is used to streamline administrative tasks such as clinical note-taking

Primary care through virtual consultations for general health-related concerns using a digital platform or mobile app. 

Antidote Health

Telehealth

Key stats

Recent Updates

Antidote Health raises USD 22 million in Series A funding

Antidote Health raises USD 22 million in Series A funding

Company Brief

Funding

Investors

About EDGE

Contact Us

Resources

Area of Focus

Technology Research Made Effortless